Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
85.64
+2.29 (2.75%)
Nov 20, 2024, 4:00 PM EST - Market closed
Intra-Cellular Therapies Revenue
Intra-Cellular Therapies had revenue of $175.38M in the quarter ending September 30, 2024, with 39.00% growth. This brings the company's revenue in the last twelve months to $613.73M, up 46.08% year-over-year. In the year 2023, Intra-Cellular Therapies had annual revenue of $464.37M with 85.51% growth.
Revenue (ttm)
$613.73M
Revenue Growth
+46.08%
P/S Ratio
14.05
Revenue / Employee
$1,006,111
Employees
610
Market Cap
9.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 464.37M | 214.06M | 85.51% |
Dec 31, 2022 | 250.31M | 166.51M | 198.69% |
Dec 31, 2021 | 83.80M | 60.99M | 267.35% |
Dec 31, 2020 | 22.81M | 22.75M | 37,537.14% |
Dec 31, 2019 | 60.61K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Ensign Group | 4.11B |
Teleflex | 3.03B |
Bio-Rad Laboratories | 2.58B |
Bio-Rad Laboratories | 2.58B |
Chemed | 2.38B |
Masimo | 2.04B |
Qiagen | 1.97B |
HealthEquity | 1.10B |
ITCI News
- 2 days ago - Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - GlobeNewsWire
- 16 days ago - Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
- 21 days ago - Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance - GlobeNewsWire
- 5 weeks ago - Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast - GlobeNewsWire
- 2 months ago - Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress - GlobeNewsWire
- 3 months ago - Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - GlobeNewsWire